The 18-ICML abstract submission is now open and will close on Saturday, 15 March 2025 (17:59 Central European Time).

Abstracts can be related to all aspects of the biology and treatment of lymphoid neoplasms, including CLL and multiple myeloma.
 

Except for Encore Abstracts (please see the relevant paragraph), abstracts must present original scientific material, unpublished at the time of the abstract submission and should not be published before the end of the 18-ICML (21 June 2025).
Updated analyses of already published material will be considered only if they contain novel information that is considered worthy of being presented.

The submission of an abstract does not constitute registration for the 18-ICML.
Presenting authors of abstracts selected for oral and poster presentations must register and attend the meeting in person, as no remote presentations will be permitted.
The early registration fee will be applied to the presenting authors of the abstracts selected for oral and poster presentation, but no reimbursement for travel and/or hotel expenses will be provided.

SPECIAL INTEREST SUBMISSIONS

Abstracts pertinent to Epigenetics and Mechanisms of resistance will be especially considered for oral presentation in the two sessions devoted to the basic and translational research topics.

Particular consideration will also be given to abstracts focusing on lymphomas in pediatric, adolescent, and young adult patients, which may be presented in the pediatric sessions.  

Specialised nurses, clinical nurse specialists, and nurse practitioners are encouraged to submit abstracts for the Oncology Nursing session, organised in collaboration with the Swiss Oncology Nursing Society (OPS / SOS), the European Oncology Nursing Society (EONS), the Haematology Nurses & Healthcare Professionals Group (HNHCP) and the European Society for Paediatric Oncology (SIOPE) Nursing Group. “Lymphoma Nursing” should be selected as a category at the time of submission.

LATE-BREAKING ABSTRACTS
 

Late-breaking abstracts (LBA) may be submitted only for studies with conclusive data available after the regular abstract submission deadline.

A cover letter indicating the data expected to be available by the late-breaking abstract deadline must be sent to abstract@icml.ch by the regular abstract deadline (15 March 2025, 17:59 CET).

No Late-breaking abstract will be considered without the submission of a cover letter.
Only abstracts covering very high-quality research findings will be accepted and possibly included in the Late-breaking abstract session.
Late-breaking abstracts not selected for oral presentation will be rejected.
 

18-ICML ABSTRACT BOOK

All abstracts selected for oral presentation, poster presentation, or “publication only” will be included in the 18-ICML Abstract Book.
The Organising Committee reserves the right to reject any abstract deemed inappropriate for publication.

The 18-ICML Abstract Book will be published as a supplement to “Haematological Oncology” (John Wiley and Sons, Inc.) in the Wiley Online Library as of Sunday, 15 June 2025.

Prior to this date, submitted abstracts must be treated as confidential by ICML (Local Organising Committee and 18-ICML reviewers), authors, and research sponsors.

ABSTRACT SUBMISSION KEY DATES AND DEADLINES